For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

27th Apr 10

Pharmaxis provides FDA resubmission for Aridol US marketing application

Pharmaxis today announced that the U.S. Food and Drug Administration has acknowledged receipt of the resubmission of its New Drug Application for Aridol™ (mannitol inhalation powder).


Read full media release - pdf
14th Apr 10

Pharmaxis Announces Milestone in Phase 3 Trial for Cystic Fibrosis

Pharmaxis today announced completion of its second six month, Phase 3 international trial assessing the effectiveness of Bronchitol in people with cystic fibrosis.


Read full media release - pdf
11th Mar 10

Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients

Pharmaxis Ltd today announced the successful completion of a Phase IIa dose profiling study with its new anti-inflammatory agent ASM8 in patients with allergic asthma.


Read full media release - pdf